› added 11 years ago
164
TIL the Supreme Court ruled the patents of breast cancer genes BRCA1 and BRCA2 by Myriad Genetics invalid. These patents previously allowed Myriad to control the price of diagnostic testing and limit any research on the breast cancer genes.